| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 64
| Issue : 6 | Page : 125-127 |
|
|
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Praveen Balabaskaran Nina1, Aditya Prasad Dash2
1 Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India
2 Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India
Correspondence Address:
Aditya Prasad Dash
Central University of Tamil Nadu, Tiruvarur, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijph.IJPH_496_20
|
|
|
Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
